Phlexglobal Opens First Office in the USA
Specialist global contract research organization
Also in the announcement, made at the 46th DIA Annual Meeting in Washington, Phlexglobal, specialists in paper and electronic trial master file solutions, unveiled Aidan Nuttall PhD as US office president.
Heading up Phlexglobal, Inc. Aidan, the co-founder and president of Abingdon Life Sciences and former president of Chiltern International’s US operation, will be working to extend the company’s client base and promote its innovative electronic Trial Master File (eTMF) services including the unique PhlexEview solution.
Phlexglobal’s move to open a US operation follows a sustained period of growth in the UK and Europe, and increasing interest from current and potential US-based client companies. Aidan said: “Phlexglobal has established itself in Europe with a portfolio of niche services and I’m looking forward to extending that to our US clients.
The opening of the US office comes only months after Phlexglobal signed a landmark contract with global biopharmaceutical company UCB to implement a complete TMF management solution in the UK and US worth £12 million over the next five years.
Nicola Murgatroyd, chief executive officer of Phlexglobal, commented: “This has been a really exciting 12 months for us, having secured the ongoing contract with UCB and with our US client base steadily growing, the next logical step was to open a US office.
“I am delighted to have Aidan on board to lead our US operation. His industry experience and contacts will be invaluable to us in promoting and delivering our services to the US clinical research market.”
Phlexglobal offers a combination of clinical trial knowledge, document management skills, technical expertise, personnel recruitment and training to the pharmaceutical, biotechnology, medical device, CRO and healthcare industries. Its electronic Trial Master File (eTMF) solution, PhlexEview, is a quality controlled end-to-end process enabling the electronic searching and viewing of centralized TMF documentation from sponsors, subsidiaries, CROs and field-based personnel.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- How the NIMBLE Study Supported Adherence With Quarterly Dosing of Cemdisiran
September 18th 2025
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025